According to a recent LinkedIn post from Glooko, the company plans to showcase its EndoTool Glucose Management System at the 2026 Society of Hospital Medicine Converge Conference. The post indicates that EndoTool, developed by Monarch Medical Technologies, a Glooko company, is positioned for use in hospital glycemic safety at a system level.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Glooko is targeting hospital customers focused on glycemic control and Centers for Medicare & Medicaid Services (CMS) reporting requirements. This emphasis on supporting CMS glycemic reporting may signal a strategy to tie the product to regulatory and reimbursement drivers, which could strengthen adoption prospects and recurring software or service revenue in the inpatient diabetes-management segment.
By highlighting participation in a major hospital medicine conference and promoting booth presence, the company appears to be investing in clinician and administrator outreach. If this visibility translates into new contracts or expanded deployments of EndoTool across hospital systems, it could enhance Glooko’s competitive positioning in digital and device-enabled glycemic management and broaden its enterprise customer base over time.